LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 2543 | 5228 | 5578 | 0.9371 | 0.8845 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 1 | P09 | 72 | hr | 2543 | 4597 | 5578 | 0.8240 | 0.6766 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 2 | P09 | 72 | hr | 2543 | 4701 | 5578 | 0.8427 | 0.7108 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 3 | P09 | 72 | hr | 2543 | 5198 | 5578 | 0.9318 | 0.8746 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 2543 | 4819 | 5578 | 0.8638 | 0.7497 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 2543 | 5136 | 5578 | 0.9207 | 0.8542 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 2543 | 5080 | 5578 | 0.9106 | 0.8357 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 1 | I03 | 72 | hr | 2543 | 4248 | 5578 | 0.7615 | 0.5616 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 2 | I03 | 72 | hr | 2543 | 4467 | 5578 | 0.8007 | 0.6337 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 2543 | 5093 | 5578 | 0.9129 | 0.8400 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 2543 | 4043 | 5578 | 0.7247 | 0.4941 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 2543 | 3927 | 5578 | 0.7039 | 0.4558 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 2543 | 4658 | 5578 | 0.8350 | 0.6967 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 1 | D15 | 72 | hr | 2543 | 5787 | 5578 | 1.0373 | 1.0686 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 2 | D15 | 72 | hr | 2543 | 5864 | 5578 | 1.0511 | 1.0940 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 3 | D15 | 72 | hr | 2543 | 5943 | 5578 | 1.0653 | 1.1200 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 2543 | 5570 | 5578 | 0.9985 | 0.9971 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 2543 | 5484 | 5578 | 0.9830 | 0.9688 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 2543 | 5796 | 5578 | 1.0390 | 1.0716 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 1 | H09 | 72 | hr | 2543 | 2110 | 5578 | 0.3782 | -0.1428 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 2 | H09 | 72 | hr | 2543 | 2042 | 5578 | 0.3660 | -0.1652 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 3 | H09 | 72 | hr | 2543 | 2256 | 5578 | 0.4044 | -0.0947 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 1 | C15 | 72 | hr | 2543 | 5412 | 5578 | 0.9701 | 0.9451 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 2 | C15 | 72 | hr | 2543 | 5466 | 5578 | 0.9798 | 0.9629 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 3 | C15 | 72 | hr | 2543 | 5394 | 5578 | 0.9669 | 0.9392 |